Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th

Onconetix, Inc. (NASDAQ:ONCO)’s stock is going to reverse split on Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 23rd.

Onconetix Stock Down 28.7 %

Shares of ONCO stock opened at $0.08 on Friday. The stock has a fifty day moving average price of $0.14 and a 200 day moving average price of $0.15. The company has a quick ratio of 0.09, a current ratio of 0.10 and a debt-to-equity ratio of 0.08. Onconetix has a 1 year low of $0.08 and a 1 year high of $0.62.

Onconetix (NASDAQ:ONCO) last announced its quarterly earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.71 million during the quarter.

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 1.37% of Onconetix as of its most recent filing with the SEC. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.